|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we investigated both the role of p63 proteins in the regulation of HβDs and the implication of these antimicrobial peptides in tumor (lymph)angiogenesis.
|
24732135 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Focal areas of the tumor demonstrated peripheral staining for p63 and CK5/6 suggestive of an in situ component.
|
29028127 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Also, a significant inverse correlation was observed between miR-223-5p and p63 expressions in tumors from patients (p = 0.0365).
|
27359057 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The role of p63 in epidermal morphogenesis and neoplasia.
|
20074064 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we show that the autophagic tumor suppressor UVRAG plays an integral role in melanogenesis by interaction with the biogenesis of lysosome-related organelles complex 1 (BLOC-1).
|
30061422 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The interplay between p53, p63 and p73 isoforms are likely to be fundamental to our understanding of tumour formation.
|
18289041 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The data indicate roles for specific p63 isoforms not only in maintaining epithelial stem cell populations, but also in cellular differentiation and neoplasia.
|
12434410 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The pathway includes the tumor supressor protein p53, its vertebrate paralogs p63 and p73, and their negative regulators MDM2 and MDM4.
|
28774266 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry for PAX8, TTF-1, thyroglobulin, mammaglobin, GCDFP-15, S-100 protein, and p63 was used to define the tumor immunophenotype.
|
27282352 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The p16 and p53 labelings were observed in some adenomas and adenocarcinomas but without any association with p63 expression, histologic type, or grade of differentiation of the neoplasm.
|
16575619 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical staining for cytokeratin cocktail and p63 has been utilized to differentiate between these tumor types.
|
28968268 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TP63 is a member of the TP53 gene family, sharing a common gene structure that produces two groups of mRNAs' encoding proteins with different N-terminal regions (ΔN and TA isoforms); both transcripts are also subjected to alternative splicing mechanisms at C-terminus, generating a variety of isoforms. p63 is a master regulator of epidermal development and homoeostasis as well as an important player in tumorigenesis and cancer progression with both oncogenic and tumour suppressive roles.
|
31789342 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we review the pro-differentiation role and tumor suppressing function of this pathway, as revealed by loss-of-function in keratinocytes and skin, downstream of p53 and in cross-connection with other determinants of stem cell potential and/or tumor formation, such as p63 and Rho/CDC42 effectors.
|
18758480 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RNA transcriptome sequencing analysis of miR-301a overexpressing prostate cancer cell lines identified the tumor suppressor p63 as a potential direct miR-301a target.
|
26990571 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Numerous studies have highlighted the oncogenic potential of the predominant p63 isoform DeltaNp63alpha; however, data suggest that other p63 proteins can act as tumor suppressors or alter the metastatic potential of tumors.
|
16885358 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Among 8 tumors positive for basal markers, cytokeratins 5 and 17 were expressed in all 8 tumors, cytokeratin 14 in 6 tumors, and p63 in 7 tumors.
|
19536621 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma.
|
21527555 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Nuclear staining for p63 was negative in 3 tested tumors.
|
23681076 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The cells grew as a cohesive sheet of suspected carcinoma origin, and western blots showed positivity for the tumour marker p63 confirming cancerous origin.
|
28846747 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results demonstrate that (1) the comparative proteomics of NEPT match the WHO classification except for AC and LCNEC; (2) SCLC show differences in their proteomics according to tumor stage; and (3) CK 18 and p63 may be useful as diagnostically and prognostically available markers.
|
16512680 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry analysis of the tumor tissue showed CK5/6 (+), p63 (+), CD56 (+), and Ki-67 (+, approximately 30%), and genetic testing detected no <i>EGFR</i> mutation.
|
31417937 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
p63 is a member of the p53 family and regulates crucial events in the formation of epithelial structures, but the role of p63 in tumor is unclear.
|
17909026 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Differences occur at the following levels: (i) protein structure, especially with regard to the aminoterminal transactivation domains and the carboxyterminal portions unique to p63 and p73; (ii) regulation, affecting mRNA levels, posttranslational modifications and interaction with other cellular proteins; (iii) activities, resulting in the regulation of gene expression, the programming of development, and the emergence of tumors.
|
15254416 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, we identified that Gli1 and Gli2 exhibited different functions in the regulation of p63 expression or proliferation of p63<sup>+</sup> cells in Kras-AR driven tumors.
|
27760825 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although p63 is detected in most osteoblastomas, it is also observed in a significant subset of osteosarcomas, severely limiting its utility in distinguishing between benign and malignant osteoblastic tumors.
|
22623071 |
2012 |